Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 11/20 | 0.51 |
| ▸ | KDR | P35968 | 6/20 | 0.47 |
| ▸ | RAF1 | P04049 | 2/20 | 0.43 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5899270 | 0.88 | KDR (0.51) | BRAFKDRRAF1CA9 | |
| SCHEMBL5899309 | 0.87 | RAF1 (0.53) | BRAFKDRRAF1MAPK3TRPV1 | |
| SCHEMBL5899281 | 0.84 | BRAF (0.44) | BRAFKDRRAF1CA9 | |
| SCHEMBL5448421 | 0.73 | TEK (0.37) | KDR | |
| SCHEMBL13556584 | 0.71 | KDR (0.82) | KDRCA9TRPV1 | |
| SCHEMBL5899323 | 0.70 | KDR (0.50) | BRAFKDRRAF1CA9 | |
| SCHEMBL11001123 | 0.70 | KDR (0.64) | BRAFKDRRAF1MAPK3CA9 | |
| SCHEMBL5899268 | 0.69 | BRAF (0.61) | BRAFKDRRAF1MAPK3CA9 | |
| SCHEMBL29364392 | 0.68 | KDR (1.00) | KDRCA9TRPV1 | |
| SCHEMBL118026 | 0.68 | KDR (1.00) | KDRCA9TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060241301-A1 | Urea derivatives and their use as tyrosinkinase inhibitors | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | US | claimed |
| US-20060241301-A1 | Urea derivatives and their use as tyrosinkinase inhibitors | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241301-A1 | Urea derivatives and their use as tyrosinkinase inhibitors | TIE1, UCK2, UTS2R | BRAF 34/4885KDR 45/4885RAF1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.